Journal of Neuro-Oncology

, Volume 78, Issue 3, pp 255–260 | Cite as

Systemic high-dose intravenous methotrexate for central nervous system metastases

  • Andrew B. Lassman
  • Lauren E. Abrey
  • Gaurav G. Shah
  • Katherine S. Panageas
  • Martin Begemann
  • Mark G. Malkin
  • Jeffrey J. Raizer
Clinical-patient studies

Summary

Background

Treatment options for patients with recurrent central nervous system (CNS) metastases are limited. Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases.

Methods

Medical records were reviewed for all patients treated with HD IV MTX (3.5 g/m2) for CNS parenchymal or leptomeningeal metastases. Radiographic response rate, survival, and toxicity were determined.

Results

Thirty-one women and one man with a median age of 52 years (range 33–76) were treated with a total of 141 cycles (median 4, range 1–13). Twenty-nine patients had breast cancer, and one each had cancer of unknown primary (CUP), squamous cell carcinoma of the head and neck, and non-small cell lung cancer (NSCLC). An objective radiographic response and stable disease were each observed in nine patients (28%), and 13 (44%) patients progressed. Prior treatment with low-dose MTX for systemic disease did not affect response (P = 0.8). The median overall survival (n = 32) was 19.9 weeks (range 2.9–135.4+) with one patient alive at 135.4 weeks. Myelosuppression and elevated serum hepatic transaminases were the most common acute toxicities (21% and 9% of HD IV MTX cycles, respectively).

Conclusions

HD IV MTX is effective in the treatment of CNS metastases with disease control (response or stable) as a best response in 56% of assessable patients. Further study is warranted.

Keywords

brain central nervous system chemotherapy leptomeninges metastases methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

Judy Lampron and Bill Carey provided key editorial and administrative assistance. Katherine Picconi and Kelly Vuksanaj cared for the majority of patients involved in this study, and we are indebted to them and to our other Neurology Nurse Practitioners. Preliminary results were presented at the 2002 American Society of Clinical Oncology and Society for Neuro-Oncology annual meetings.

This work was supported in part by the American Brain Tumor Association and grant number CA009512 from the National Cancer Institute.

References

  1. 1.
    Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI, 1999 Identification of prognostic factors in patients with brain metastases: a review of 1292 patients Int J Radiat Oncol Biol Phys 43: 795–803CrossRefPubMedGoogle Scholar
  2. 2.
    Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ, 1998 High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16: 1561–1567PubMedGoogle Scholar
  3. 3.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92: 205–216CrossRefPubMedGoogle Scholar
  4. 4.
    Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG, 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8: 1277–1280PubMedGoogle Scholar
  5. 5.
    Begemann M, Rosenblum MK, Loh J, Kraus D, Raizer JJ, 2003 Leptomeningeal metastases from recurrent squamous cell cancer of the skin J Neurooncol 63: 295–298CrossRefPubMedGoogle Scholar
  6. 6.
    Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB, 1999 A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors Clin Cancer Res 5: 3394–3402PubMedGoogle Scholar
  7. 7.
    Jaeckle KA, Batchelor T, O’Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB, 2002 An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis J Neurooncol 57: 231–239CrossRefPubMedGoogle Scholar
  8. 8.
    Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS, 1993 Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis Eastern Cooperative Oncology Group J Clin Oncol 11: 561–569PubMedGoogle Scholar
  9. 9.
    Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH, 2000 Ommaya reservoirs for the treatment of leptomeningeal metastases Neurosurgery 47: 49–54CrossRefPubMedGoogle Scholar
  10. 10.
    Lassman AB, DeAngelis LM, 2003 Brain metastases Neurol Clin 21: 1–23CrossRefPubMedGoogle Scholar
  11. 11.
    Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG, 2001 A phase II trial of temozolomide for patients with recurrent or progressive brain metastases J Neurooncol 53: 259–265CrossRefPubMedGoogle Scholar
  12. 12.
    Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV, 2001 Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases Ann Oncol 12: 249–254CrossRefPubMedGoogle Scholar
  13. 13.
    Siena S, Landonio E, Baietta E, Vitali M, Crino L, Danova M, Musolino A, Gardin G, Fao P, Fincato G, 2003 Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (Abstract 407) Proc Am Soc Clin Oncol 22: 102Google Scholar
  14. 14.
    Wong ET, Berkenblit A, 2004 The role of topotecan in the treatment of brain metastases Oncologist 9: 68–79CrossRefPubMedGoogle Scholar
  15. 15.
    Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL, 2001 Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer Am J Clin Oncol 24: 421–424CrossRefPubMedGoogle Scholar
  16. 16.
    Siegelmann-Danieli N, Stein M, Bar-Ziv J, 2003 Complete response of brain metastases originating in breast cancer to capecitabine therapy Isr Med Assoc J 5: 833–834PubMedGoogle Scholar
  17. 17.
    Posner JB: 1995 Neurologic complications of cancer F.A. Davis Company, Philadelphia, p 78Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Andrew B. Lassman
    • 1
    • 5
  • Lauren E. Abrey
    • 1
  • Gaurav G. Shah
    • 1
  • Katherine S. Panageas
    • 2
  • Martin Begemann
    • 3
  • Mark G. Malkin
    • 4
  • Jeffrey J. Raizer
    • 5
  1. 1.Departments of NeurologyMemorial Sloan-Kettering Cancer Center New YorkUSA
  2. 2.Epidemiology, Biostatistics, Memorial Sloan-Kettering Cancer Center New YorkUSA
  3. 3.Department of NeurologyMax Planck Institute for Molecular Genetics BerlinGermany
  4. 4.Department of NeurologyMedical College of WisconsinMilwaukeeUSA
  5. 5.Department of NeurologyNorthwestern University, Feinberg School of Medicine and Robert H. Lurie Cancer CenterChicagoUSA

Personalised recommendations